Eddingpharm (Cayman) Inc. Announces Closing of $24 Million Series B Funding

WANCHAI, Hong Kong, Sept. 17 /PRNewswire/ -- Eddingpharm (Cayman) Inc., a leading specialty pharmaceutical marketing company focused on the China market, today announced the closing of a US$24 million Series B financing, co-led by OrbiMed Advisors Caduceus Asia Partners Fund and Domain Associates. Sequoia Capital China Growth Fund also participated in the financing. The financing will be used primarily for in-licensing of drugs from suppliers across the globe and co-development of new prescription drugs for sale in China, as well as to seek potential M&A opportunities. William Blair & Company, LLC acted as placement agent for the transaction.